Virtu Financial LLC Sells 4,489 Shares of Johnson & Johnson (NYSE:JNJ)

Virtu Financial LLC lessened its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 60.6% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,914 shares of the company's stock after selling 4,489 shares during the quarter. Virtu Financial LLC's holdings in Johnson & Johnson were worth $472,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also added to or reduced their stakes in the company. Innealta Capital LLC purchased a new position in shares of Johnson & Johnson in the second quarter worth $27,000. Highline Wealth Partners LLC purchased a new position in shares of Johnson & Johnson in the third quarter valued at about $31,000. RPg Family Wealth Advisory LLC bought a new position in shares of Johnson & Johnson during the third quarter valued at about $35,000. Mowery & Schoenfeld Wealth Management LLC boosted its holdings in shares of Johnson & Johnson by 58.7% during the third quarter. Mowery & Schoenfeld Wealth Management LLC now owns 246 shares of the company's stock worth $40,000 after purchasing an additional 91 shares during the period. Finally, Activest Wealth Management bought a new stake in shares of Johnson & Johnson in the third quarter worth about $40,000. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson Stock Down 1.9 %

Shares of NYSE JNJ traded down $2.78 during trading on Monday, reaching $143.84. The company had a trading volume of 8,728,601 shares, compared to its average volume of 7,130,328. The business's 50-day moving average is $156.73 and its 200 day moving average is $156.44. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45. The stock has a market cap of $346.30 billion, a PE ratio of 21.22, a P/E/G ratio of 2.52 and a beta of 0.51. Johnson & Johnson has a 12-month low of $143.13 and a 12-month high of $168.85.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings data on Tuesday, October 15th. The company reported $2.42 earnings per share for the quarter, beating analysts' consensus estimates of $2.21 by $0.21. The business had revenue of $22.47 billion during the quarter, compared to analyst estimates of $22.17 billion. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. Johnson & Johnson's revenue was up 5.2% compared to the same quarter last year. During the same period last year, the business earned $2.66 EPS. As a group, equities analysts forecast that Johnson & Johnson will post 9.94 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th were issued a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.45%. The ex-dividend date of this dividend was Tuesday, November 26th. Johnson & Johnson's payout ratio is 71.78%.

Insider Activity

In other Johnson & Johnson news, Director Mark A. Weinberger bought 1,000 shares of the firm's stock in a transaction on Thursday, December 12th. The stock was acquired at an average price of $147.22 per share, with a total value of $147,220.00. Following the transaction, the director now owns 1,000 shares in the company, valued at $147,220. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 0.16% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the company. StockNews.com upgraded Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a report on Saturday, September 14th. Wolfe Research initiated coverage on shares of Johnson & Johnson in a report on Friday, November 15th. They issued an "outperform" rating and a $190.00 price target on the stock. Wells Fargo & Company upped their price objective on shares of Johnson & Johnson from $163.00 to $166.00 and gave the stock an "equal weight" rating in a report on Wednesday, October 16th. Bank of America reiterated a "neutral" rating and set a $166.00 price target on shares of Johnson & Johnson in a research report on Tuesday, December 10th. Finally, Guggenheim raised their price objective on shares of Johnson & Johnson from $156.00 to $162.00 and gave the stock a "neutral" rating in a report on Wednesday, November 6th. Seven analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $174.73.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.